PRRT2 and cancer: Eventhough AAK1 and GAK are not among the cancer targets of these compounds, they are very potently bound and inhibited by sunitinib or PKC-412 and erlotinib, respectively (with Kds of binding that are lower or comparable to the major cancer targets).